Telix Pharmaceuticals Limited (ASX:TLX) (NASDAQ:TLX) has announced a transformational Merger agreement to acquire ITM Isotope Technologies Munich SE (ITM), a global leader in radioisotope production and radiopharmaceutical development, for an upfront consideration of US$1.65 billion on a cash-free/debt-free basis. The transaction, which is subject to Telix Shareholder approval and customary regulatory conditions, is expected to close by the end of FY2026. Upon completion, Telix shareholders will own approximately 76.3% of the combined entity and ITM shareholders approximately 23.7%.

Deal Structure and Consideration

Under the terms of the agreement, the US$1.65 billion upfront consideration will be structured as follows: US$1.25 billion will be paid to ITM sellers in the form of 105.8 million Telix shares, priced at the 30-day trailing VWAP as of signing of US$11.84 per share, released as Nasdaq-listed ADRs after their respective Escrow periods of up to 15 months; US$302 million of net Debt will be assumed by Telix at closing; and US$96 million of management Equity rollover and transaction expenses payable by the sellers, each subject to closing adjustments.

Additional contingent consideration of up to US$700 million will become payable upon achievement of regulatory approvals and commercial sales milestones for ITM-11. This includes up to US$250 million upon FDA approval across three GEP-NET and lung NET indications by specified dates through 2031, and up to US$450 million based on ITM-11 net global sales in FY2030 exceeding US$150 million. All milestone consideration is payable in cash or shares at Telix's election. Morgan Stanley Australia acted as exclusive financial adviser to Telix; Centerview Partners acted for ITM.

Strategic Rationale: Isotope Supply and Manufacturing

ITM is the world's leading supplier of therapeutic radioisotopes and the only producer of globally scaled commercial-grade lutetium-177 (177Lu) — a radioisotope that is central to a growing number of targeted radionuclide therapies. ITM's Manufacturing network spans over 65 countries and generated Revenue of US$273 million in 2025, representing a CAGR of 40% from 2021 to 2025. ITM's commercial-scale and profitable isotope production Business contributes to cash generation while deepening Telix's supply chain for isotopes required for its therapeutics pipeline. For Telix, which has multiple therapeutic programmes reliant on 177Lu supply, the Acquisition eliminates a structural supply chain dependency and converts an external cost into an internal capability.

ITM's manufacturing infrastructure includes two GMP manufacturing sites and, through its agreement with Isogen, 15-year exclusive access to Bruce Power's nuclear reactors in Canada for the irradiation services required to manufacture 177Lu. This secured reactor access provides a meaningful long-term supply chain advantage in a market where isotope availability is a limiting Factor for the broader radiopharmaceutical industry.

Pipeline Addition: ITM-11 for GEP-NETs

Beyond the manufacturing and supply chain rationale, the merger also adds a complementary late-stage therapeutic pipeline asset. ITM-11 (177Lu-edotreotide) is a somatostatin receptor-targeted treatment for gastroenteropancreatic neuroendocrine tumors (GEP-NETs) that has successfully completed a Phase 3 trial (the COMPETE study). A second Phase 3 study (COMPOSE) is fully enrolled and an interim analysis is expected in H1 2027. GEP-NETs represent a commercially validated and clinically significant market for targeted radionuclide therapy, and if approved, ITM-11 could accelerate Telix's entry into the commercial therapeutic market and expand its presence in the neuroendocrine tumour segment.

Financial Outlook and Revenue Profile

The combined organisation is expected to generate unaudited pro forma 2026 revenue and income exceeding US$1.3 billion, based on management estimates. The transaction is expected to support a positive EBITDA contribution from 2027, contingent on the realisation of targeted synergies and commercial timing assumptions, and excluding one-off implementation costs. The manufacturing business is already profitable and cash-generating, which distinguishes this acquisition from typical pharmaceutical acquisitions where revenue and profitability may be years away.

It is worth noting that the contingent consideration of up to US$700 million is milestone-based and not guaranteed. FDA approval timelines for ITM-11, commercial uptake after any approval, and the realisation of synergies are all subject to risks that investors in radiopharmaceutical development companies should weigh carefully. A Notice of Meeting for an extraordinary general meeting is expected to be sent to Telix shareholders in November 2026.

Key Insights

Telix's acquisition of ITM is a strategically coherent transaction that addresses two distinct value creation levers simultaneously: securing the isotope supply chain that underpins its therapeutic pipeline, and adding a Phase 3-ready clinical asset in GEP-NETs that could generate near-term therapeutic revenue if approved. The US$273 million revenue base and profitable manufacturing operations at ITM provide financial grounding for the US$1.65 billion headline consideration. The contingent US$700 million milestones tied to ITM-11 provide structured upside if regulatory and commercial outcomes are achieved, without front-loading the consideration in a binary pharmaceutical bet. The key risks centre on FDA approval timelines for ITM-11, integration execution, and the assumptions underpinning the 2027 EBITDA target.